Atea Pharmaceuticals, Inc. (AVIR) Friday said its Phase 3 SUNRISE-3 study of bemnifosbuvir for the treatment of Covid-19 failed to meet the primary goal.
In the study, high-risk patients with mild or moderate COVID-19 were randomized to receive bemnifosbuvir or placebo. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through day 29.
Bemnifosbuvir is in Phase 2 study in combination with ruzasvir for the treatment of hepatitis c virus (HCV) infection. The company plans to announce additional results from the study in the fourth quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.